You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEnalapril
Accession NumberDB00584  (APRD00510)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionEnalapril is a prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to enalaprilat following oral administration. Enalaprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Enalapril may be used to treat essential or renovascular hypertension and symptomatic congestive heart failure.
Structure
Thumb
Synonyms
(S)-1-(N-(1-(Ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-L-proline
(S)-1-{(S)-2-[1-((S)-ethoxycarbonyl)-3-phenyl-propylamino]-propionyl}-pyrrolidine-2-carboxylic acid
1-(N-((S)-1-Carboxy-3-phenylpropyl)-L-alanyl)-L-proline 1'-ethyl ester
Analapril
Enalapril
Enalaprila
Enalaprilum
External Identifiers
  • L 154739-01 D
  • MK 421
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act EnalaprilTablet2 mgOralActavis Pharma Company2007-10-17Not applicableCanada
Act EnalaprilTablet4 mgOralActavis Pharma Company2007-10-17Not applicableCanada
Act EnalaprilTablet8 mgOralActavis Pharma Company2007-10-17Not applicableCanada
Act EnalaprilTablet16 mgOralActavis Pharma Company2007-10-17Not applicableCanada
Ava-enalaprilTablet2.5 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-enalaprilTablet5.0 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-enalaprilTablet10.0 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-enalaprilTablet20.0 mgOralAvanstra Inc2011-10-112014-08-21Canada
Dom-enalaprilTablet2.0 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-enalaprilTablet4 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-enalaprilTablet8 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-enalaprilTablet16 mgOralDominion PharmacalNot applicableNot applicableCanada
EnalaprilTablet16 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
EnalaprilTablet8 mgOralFrosst A Division Of Merck Canada IncNot applicableNot applicableCanada
EnalaprilTablet16 mgOralSivem Pharmaceuticals Ulc2015-08-10Not applicableCanada
EnalaprilTablet16 mgOralSanis Health Inc2013-02-13Not applicableCanada
EnalaprilTablet2.0 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
EnalaprilTablet2 mgOralSanis Health Inc2013-02-13Not applicableCanada
EnalaprilTablet16 mgOralFrosst A Division Of Merck Canada IncNot applicableNot applicableCanada
EnalaprilTablet2 mgOralSivem Pharmaceuticals Ulc2015-08-10Not applicableCanada
EnalaprilTablet4.0 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
EnalaprilTablet4 mgOralSanis Health Inc2013-02-13Not applicableCanada
EnalaprilTablet2 mgOralFrosst A Division Of Merck Canada IncNot applicableNot applicableCanada
EnalaprilTablet4 mgOralSivem Pharmaceuticals Ulc2015-08-10Not applicableCanada
EnalaprilTablet8.0 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
EnalaprilTablet8 mgOralSanis Health Inc2013-02-13Not applicableCanada
EnalaprilTablet4 mgOralFrosst A Division Of Merck Canada IncNot applicableNot applicableCanada
EnalaprilTablet8 mgOralSivem Pharmaceuticals Ulc2015-08-10Not applicableCanada
Enalapril MaleateTablet5 mg/1OralOceanside Pharmaceuticals1985-12-24Not applicableUs
Enalapril MaleateTablet10 mg/1OralOceanside Pharmaceuticals1985-12-24Not applicableUs
Enalapril MaleateTablet20 mg/1OralOceanside Pharmaceuticals1985-12-24Not applicableUs
Enalapril MaleateTablet2.5 mg/1OralOceanside Pharmaceuticals1988-07-26Not applicableUs
EpanedKitSilvergate Pharmaceuticals, Inc.2013-08-22Not applicableUs
EpanedSolution1 mg/mLOralSilvergate Pharmaceuticals, Inc.2016-10-03Not applicableUs
Mar-enalaprilTablet10 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-enalaprilTablet20 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mylan-enalaprilTablet16 mgOralMylan Pharmaceuticals Ulc2007-10-17Not applicableCanada
Mylan-enalaprilTablet2 mgOralMylan Pharmaceuticals Ulc2007-10-17Not applicableCanada
Mylan-enalaprilTablet4 mgOralMylan Pharmaceuticals Ulc2007-10-17Not applicableCanada
Mylan-enalaprilTablet8 mgOralMylan Pharmaceuticals Ulc2007-10-17Not applicableCanada
Ntp-enalaprilTablet16 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-enalaprilTablet2 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-enalaprilTablet32 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-enalaprilTablet4 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-enalaprilTablet8 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Nu-enalaprilTablet2.5 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-enalaprilTablet5 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-enalaprilTablet10 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-enalaprilTablet20 mgOralNu Pharm IncNot applicableNot applicableCanada
PMS-enalaprilTablet16 mgOralPharmascience Inc2007-11-23Not applicableCanada
PMS-enalaprilTablet2.0 mgOralPharmascience Inc2007-11-23Not applicableCanada
PMS-enalaprilTablet4 mgOralPharmascience Inc2007-11-23Not applicableCanada
PMS-enalaprilTablet8 mgOralPharmascience Inc2007-11-23Not applicableCanada
Pro-enalapril - 10Tablet10 mgOralPro Doc Limitee2008-07-04Not applicableCanada
Pro-enalapril - 2.5Tablet2.5 mgOralPro Doc Limitee2008-07-04Not applicableCanada
Pro-enalapril - 20Tablet20 mgOralPro Doc Limitee2008-07-04Not applicableCanada
Pro-enalapril - 5Tablet5 mgOralPro Doc Limitee2008-07-04Not applicableCanada
Ran-enalaprilTablet4 mgOralRanbaxy Pharmaceuticals Canada Inc.2010-08-01Not applicableCanada
Ran-enalaprilTablet8 mgOralRanbaxy Pharmaceuticals Canada Inc.2010-08-01Not applicableCanada
Ran-enalaprilTablet16 mgOralRanbaxy Pharmaceuticals Canada Inc.2010-08-01Not applicableCanada
Ran-enalaprilTablet2 mgOralRanbaxy Pharmaceuticals Canada Inc.2010-08-01Not applicableCanada
Ratio-enalaprilTablet4.0 mgOralRatiopharm Inc Division Of Teva Canada Limited2007-10-172014-09-19Canada
Ratio-enalaprilTablet8.0 mgOralRatiopharm Inc Division Of Teva Canada Limited2007-10-172014-09-19Canada
Ratio-enalaprilTablet16 mgOralRatiopharm Inc Division Of Teva Canada Limited2007-10-172014-09-19Canada
Ratio-enalaprilTablet2.0 mgOralRatiopharm Inc Division Of Teva Canada Limited2007-10-172014-09-19Canada
Riva-enalaprilTablet8.0 mgOralLaboratoire Riva Inc2007-10-20Not applicableCanada
Riva-enalaprilTablet16 mgOralLaboratoire Riva Inc2007-10-20Not applicableCanada
Riva-enalaprilTablet2.0 mgOralLaboratoire Riva Inc2007-10-20Not applicableCanada
Riva-enalaprilTablet4.0 mgOralLaboratoire Riva Inc2007-10-20Not applicableCanada
Sandoz EnalaprilTablet2.0 mgOralSandoz Canada Incorporated2007-10-17Not applicableCanada
Sandoz EnalaprilTablet4.0 mgOralSandoz Canada Incorporated2007-10-17Not applicableCanada
Sandoz EnalaprilTablet8.0 mgOralSandoz Canada Incorporated2007-10-17Not applicableCanada
Sandoz EnalaprilTablet16 mgOralSandoz Canada Incorporated2007-10-17Not applicableCanada
Sig-enalaprilTablet4.0 mgOralSigmacon Lifesciences Inc2009-04-302015-08-02Canada
Sig-enalaprilTablet8.0 mgOralSigmacon Lifesciences Inc2009-04-302015-08-02Canada
Sig-enalaprilTablet16 mgOralSigmacon Lifesciences Inc2009-04-302015-08-02Canada
Sig-enalaprilTablet2.0 mgOralSigmacon Lifesciences Inc2009-04-302015-08-02Canada
Taro-enalaprilTablet16 mgOralTaro Pharmaceuticals Inc2007-11-06Not applicableCanada
Taro-enalaprilTablet2.0 mgOralTaro Pharmaceuticals Inc2007-11-06Not applicableCanada
Taro-enalaprilTablet4 mgOralTaro Pharmaceuticals Inc2007-11-06Not applicableCanada
Taro-enalaprilTablet8 mgOralTaro Pharmaceuticals Inc2007-11-06Not applicableCanada
Teva-enalaprilTablet4 mgOralTeva Canada Limited1998-08-31Not applicableCanada
Teva-enalaprilTablet2.0 mgOralTeva Canada Limited2007-10-17Not applicableCanada
Teva-enalaprilTablet8 mgOralTeva Canada Limited1998-08-31Not applicableCanada
Teva-enalaprilTablet32 mgOralTeva Canada Limited2009-09-15Not applicableCanada
Teva-enalaprilTablet16 mgOralTeva Canada Limited2007-10-17Not applicableCanada
VasotecTablet2 mgOralMerck Canada Inc1990-12-31Not applicableCanada
VasotecTablet16 mgOralMerck Canada Inc1987-12-31Not applicableCanada
VasotecTablet2.5 mg/1OralValeant Pharmaceuticals North America LLC1988-07-26Not applicableUs
VasotecTablet10 mg/1OralREMEDYREPACK INC.2014-10-24Not applicableUs
VasotecTablet4 mgOralMerck Canada Inc1987-12-31Not applicableCanada
VasotecTablet5 mg/1OralValeant Pharmaceuticals North America LLC1985-12-24Not applicableUs
VasotecTablet20 mg/1OralREMEDYREPACK INC.2015-02-25Not applicableUs
VasotecTablet10 mg/1OralValeant Pharmaceuticals North America LLC1985-12-24Not applicableUs
VasotecTablet5 mg/1OralREMEDYREPACK INC.2015-02-25Not applicableUs
VasotecTablet8 mgOralMerck Canada Inc1987-12-31Not applicableCanada
VasotecTablet20 mg/1OralValeant Pharmaceuticals North America LLC1985-12-24Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-enalapril Tab 10mgTablet10 mgOralApotex Inc1993-12-31Not applicableCanada
Apo-enalapril Tab 2.5mgTablet2.5 mgOralApotex Inc1993-12-31Not applicableCanada
Apo-enalapril Tab 20mgTablet20 mgOralApotex Inc1993-12-31Not applicableCanada
Apo-enalapril Tab 5mgTablet5 mgOralApotex Inc1993-12-31Not applicableCanada
Enalapril MaleateTablet5 mg/1OralNorthstar Rx LLC2015-08-06Not applicableUs
Enalapril MaleateTablet20 mg/1OralMylan Pharmaceuticals Inc.2000-08-22Not applicableUs
Enalapril MaleateTablet20 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2001-01-232016-02-06Us
Enalapril MaleateTablet20 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2001-01-23Not applicableUs
Enalapril MaleateTablet20 mg/1OralPhysicians Total Care, Inc.2002-01-02Not applicableUs
Enalapril MaleateTablet10 mg/1OralSt Marys Medical Park Pharmacy2014-01-23Not applicableUs
Enalapril MaleateTablet2.5 mg/1OralMylan Institutional Inc.2000-11-15Not applicableUs
Enalapril MaleateTablet5 mg/1OralContract Pharmacy Services Pa2010-04-07Not applicableUs
Enalapril MaleateTablet20 mg/1OralA S Medication Solutions2009-12-11Not applicableUs
Enalapril MaleateTablet2.5 mg/1Oralbryant ranch prepack2001-01-23Not applicableUs
Enalapril MaleateTablet2.5 mg/1OralLegacy Pharmaceutical Packaging, Llc2009-12-11Not applicableUs
Enalapril MaleateTablet5 mg/1OralUnit Dose Services2009-12-11Not applicableUs
Enalapril MaleateTablet10 mg/1OralBlenheim Pharmacal, Inc.2011-04-18Not applicableUs
Enalapril MaleateTablet2.5 mg/1OralTeva Pharmaceuticals USA Inc2000-08-23Not applicableUs
Enalapril MaleateTablet2.5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2000-08-22Not applicableUs
Enalapril MaleateTablet5 mg/1OralMed Health Pharma, LLC2011-01-01Not applicableUs
Enalapril MaleateTablet5 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Enalapril MaleateTablet10 mg/1OralPd Rx Pharmaceuticals, Inc.2009-12-11Not applicableUs
Enalapril MaleateTablet5 mg/1OralMajor Pharmaceuticals2004-02-03Not applicableUs
Enalapril MaleateTablet2.5 mg/1OralWockhardt USA LLC.2009-12-11Not applicableUs
Enalapril MaleateTablet5 mg/1OralREMEDYREPACK INC.2007-04-032016-11-22Us
Enalapril MaleateTablet5 mg/1OralREMEDYREPACK INC.2013-05-09Not applicableUs
Enalapril MaleateTablet10 mg/1OralCardinal Health2004-02-03Not applicableUs
Enalapril MaleateTablet10 mg/1OralDIRECT RX2015-12-03Not applicableUs
Enalapril MaleateTablet2.5 mg/1OralGolden State Medical Supply, Inc.2013-11-04Not applicableUs
Enalapril MaleateTablet20 mg/1OralContract Pharmacy Services Pa2010-08-02Not applicableUs
Enalapril MaleateTablet10 mg/1OralRanbaxy Pharmaceuticals Inc.2016-09-17Not applicableUs
Enalapril MaleateTablet, soluble2.5 mg/1OralApace Packaging2009-08-22Not applicableUs
Enalapril MaleateTablet10 mg/1OralRebel Distributors Corp2009-12-11Not applicableUs
Enalapril MaleateTablet20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-12-11Not applicableUs
Enalapril MaleateTablet2.5 mg/1OralUnit Dose Services2009-12-11Not applicableUs
Enalapril MaleateTablet2.5 mg/1OralMylan Pharmaceuticals Inc.2000-08-22Not applicableUs
Enalapril MaleateTablet2.5 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2001-01-232016-02-06Us
Enalapril MaleateTablet2.5 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2001-01-23Not applicableUs
Enalapril MaleateTablet2.5 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Enalapril MaleateTablet5 mg/1OralWockhardt Limited2009-12-11Not applicableUs
Enalapril MaleateTablet10 mg/1OralREMEDYREPACK INC.2007-12-05Not applicableUs
Enalapril MaleateTablet5 mg/1OralTYA Pharmaceuticals2009-12-11Not applicableUs
Enalapril MaleateTablet20 mg/1OralA S Medication Solutions2009-12-11Not applicableUs
Enalapril MaleateTablet2.5 mg/1OralGolden State Medical Supply, Inc.2011-05-122015-11-30Us
Enalapril MaleateTablet20 mg/1OralPreferred Pharmaceuticals, Inc.2012-01-17Not applicableUs
Enalapril MaleateTablet20 mg/1OralBlenheim Pharmacal, Inc.2014-02-20Not applicableUs
Enalapril MaleateTablet10 mg/1OralContract Pharmacy Services Pa2010-04-07Not applicableUs
Enalapril MaleateTablet10 mg/1OralREMEDYREPACK INC.2016-10-12Not applicableUs
Enalapril MaleateTablet10 mg/1OralRed Pharm Drug, Inc.2009-12-11Not applicableUs
Enalapril MaleateTablet10 mg/1OralNorthstar Rx LLC2015-08-06Not applicableUs
Enalapril MaleateTablet2.5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-12-11Not applicableUs
Enalapril MaleateTablet2.5 mg/1OralREMEDYREPACK INC.2011-10-052016-11-29Us
Enalapril MaleateTablet5 mg/1OralREMEDYREPACK INC.2013-03-11Not applicableUs
Enalapril MaleateTablet2.5 mg/1OralPhysicians Total Care, Inc.2002-09-12Not applicableUs
Enalapril MaleateTablet2.5 mg/1OralSt Marys Medical Park Pharmacy2014-01-23Not applicableUs
Enalapril MaleateTablet5 mg/1OralMylan Institutional Inc.2000-11-15Not applicableUs
Enalapril MaleateTablet5 mg/1OralPd Rx Pharmaceuticals, Inc.2009-12-11Not applicableUs
Enalapril MaleateTablet2.5 mg/1OralMajor Pharmaceuticals2004-02-03Not applicableUs
Enalapril MaleateTablet5 mg/1OralWockhardt USA LLC.2009-12-11Not applicableUs
Enalapril MaleateTablet5 mg/1OralA S Medication Solutions2009-12-11Not applicableUs
Enalapril MaleateTablet5 mg/1OralLegacy Pharmaceutical Packaging, Llc2009-12-11Not applicableUs
Enalapril MaleateTablet2.5 mg/1OralUnit Dose Services2009-12-112016-11-22Us
Enalapril MaleateTablet10 mg/1OralBlenheim Pharmacal, Inc.2013-11-25Not applicableUs
Enalapril MaleateTablet5 mg/1OralTeva Pharmaceuticals USA Inc2000-08-23Not applicableUs
Enalapril MaleateTablet10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2009-12-11Not applicableUs
Enalapril MaleateTablet10 mg/1OralMed Health Pharma, LLC2011-01-01Not applicableUs
Enalapril MaleateTablet10 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Enalapril MaleateTablet5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2000-08-22Not applicableUs
Enalapril MaleateTablet10 mg/1OralUnit Dose Services2009-12-11Not applicableUs
Enalapril MaleateTablet20 mg/1OralREMEDYREPACK INC.2013-05-15Not applicableUs
Enalapril MaleateTablet5 mg/1OralCardinal Health2004-02-03Not applicableUs
Enalapril MaleateTablet5 mg/1Oralbryant ranch prepack2009-12-11Not applicableUs
Enalapril MaleateTablet5 mg/1OralGolden State Medical Supply, Inc.2013-11-04Not applicableUs
Enalapril MaleateTablet5 mg/1OralAmerican Health Packaging2009-05-26Not applicableUs
Enalapril MaleateTablet20 mg/1OralRanbaxy Pharmaceuticals Inc.2016-09-17Not applicableUs
Enalapril MaleateTablet, soluble5 mg/1OralApace Packaging2009-08-22Not applicableUs
Enalapril MaleateTablet20 mg/1OralRebel Distributors Corp2009-12-11Not applicableUs
Enalapril MaleateTablet5 mg/1OralMylan Pharmaceuticals Inc.2000-08-22Not applicableUs
Enalapril MaleateTablet5 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2001-01-232016-02-06Us
Enalapril MaleateTablet5 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2001-01-23Not applicableUs
Enalapril MaleateTablet2.5 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Enalapril MaleateTablet10 mg/1OralWockhardt Limited2009-12-11Not applicableUs
Enalapril MaleateTablet20 mg/1OralREMEDYREPACK INC.2009-09-162016-11-01Us
Enalapril MaleateTablet20 mg/1OralDispensing Solutions, Inc.2009-12-11Not applicableUs
Enalapril MaleateTablet5 mg/1OralA S Medication Solutions2009-12-11Not applicableUs
Enalapril MaleateTablet5 mg/1OralGolden State Medical Supply, Inc.2011-05-122015-11-30Us
Enalapril MaleateTablet10 mg/1OralPreferred Pharmaceuticals, Inc.2012-01-17Not applicableUs
Enalapril MaleateTablet10 mg/1OralSTAT Rx USA LLC2009-12-11Not applicableUs
Enalapril MaleateTablet5 mg/1OralPhysicians Total Care, Inc.2000-11-29Not applicableUs
Enalapril MaleateTablet20 mg/1OralSt Marys Medical Park Pharmacy2014-04-21Not applicableUs
Enalapril MaleateTablet10 mg/1OralMylan Institutional Inc.2000-11-15Not applicableUs
Enalapril MaleateTablet20 mg/1OralContract Pharmacy Services Pa2010-06-28Not applicableUs
Enalapril MaleateTablet2.5 mg/1OralRanbaxy Pharmaceuticals Inc.2016-09-17Not applicableUs
Enalapril MaleateTablet5 mg/1OralUnit Dose Services2009-12-11Not applicableUs
Enalapril MaleateTablet20 mg/1OralNorthstar Rx LLC2015-08-06Not applicableUs
Enalapril MaleateTablet5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-12-11Not applicableUs
Enalapril MaleateTablet20 mg/1OralUnit Dose Services2009-12-11Not applicableUs
Enalapril MaleateTablet20 mg/1OralREMEDYREPACK INC.2013-03-14Not applicableUs
Enalapril MaleateTablet20 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Enalapril MaleateTablet20 mg/1OralPd Rx Pharmaceuticals, Inc.2009-12-11Not applicableUs
Enalapril MaleateTablet10 mg/1OralMajor Pharmaceuticals2004-02-03Not applicableUs
Enalapril MaleateTablet10 mg/1OralWockhardt USA LLC.2009-12-11Not applicableUs
Enalapril MaleateTablet10 mg/1OralA S Medication Solutions2009-12-11Not applicableUs
Enalapril MaleateTablet10 mg/1OralLegacy Pharmaceutical Packaging, Llc2009-12-11Not applicableUs
Enalapril MaleateTablet10 mg/1OralUnit Dose Services2009-12-112016-11-22Us
Enalapril MaleateTablet5 mg/1OralBlenheim Pharmacal, Inc.2013-12-10Not applicableUs
Enalapril MaleateTablet10 mg/1OralTeva Pharmaceuticals USA Inc2000-08-23Not applicableUs
Enalapril MaleateTablet20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2009-12-11Not applicableUs
Enalapril MaleateTablet20 mg/1OralMed Health Pharma, LLC2011-01-01Not applicableUs
Enalapril MaleateTablet10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2000-08-22Not applicableUs
Enalapril MaleateTablet5 mg/1OralUnit Dose Services2009-12-11Not applicableUs
Enalapril MaleateTablet10 mg/1OralREMEDYREPACK INC.2013-05-23Not applicableUs
Enalapril MaleateTablet10 mg/1OralCardinal Health2010-10-13Not applicableUs
Enalapril MaleateTablet2.5 mg/1Oralbryant ranch prepack2009-12-11Not applicableUs
Enalapril MaleateTablet10 mg/1OralGolden State Medical Supply, Inc.2013-11-04Not applicableUs
Enalapril MaleateTablet10 mg/1OralAmerican Health Packaging2009-05-26Not applicableUs
Enalapril MaleateTablet10 mg/1OralNu Care Pharmaceuticals, Inc.2009-12-11Not applicableUs
Enalapril MaleateTablet, soluble10 mg/1OralApace Packaging2009-08-22Not applicableUs
Enalapril MaleateTablet10 mg/1OralREMEDYREPACK INC.2013-06-142016-10-25Us
Enalapril MaleateTablet2.5 mg/1OralNorthstar Rx LLC2015-08-06Not applicableUs
Enalapril MaleateTablet10 mg/1OralMylan Pharmaceuticals Inc.2000-08-22Not applicableUs
Enalapril MaleateTablet10 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2001-01-232016-02-06Us
Enalapril MaleateTablet10 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2001-01-23Not applicableUs
Enalapril MaleateTablet2.5 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Enalapril MaleateTablet20 mg/1OralWockhardt Limited2009-12-11Not applicableUs
Enalapril MaleateTablet2.5 mg/1OralREMEDYREPACK INC.2010-09-17Not applicableUs
Enalapril MaleateTablet5 mg/1OralContract Pharmacy Services Pa2010-08-02Not applicableUs
Enalapril MaleateTablet10 mg/1OralA S Medication Solutions2009-12-11Not applicableUs
Enalapril MaleateTablet10 mg/1OralGolden State Medical Supply, Inc.2011-05-122015-11-30Us
Enalapril MaleateTablet5 mg/1OralPreferred Pharmaceuticals, Inc.2012-01-17Not applicableUs
Enalapril MaleateTablet10 mg/1OralPhysicians Total Care, Inc.2000-11-29Not applicableUs
Enalapril MaleateTablet5 mg/1OralSt Marys Medical Park Pharmacy2014-04-21Not applicableUs
Enalapril MaleateTablet20 mg/1OralMylan Institutional Inc.2000-11-15Not applicableUs
Enalapril MaleateTablet10 mg/1OralContract Pharmacy Services Pa2010-08-02Not applicableUs
Enalapril MaleateTablet5 mg/1OralRanbaxy Pharmaceuticals Inc.2016-09-17Not applicableUs
Enalapril MaleateTablet20 mg/1OralREMEDYREPACK INC.2016-12-01Not applicableUs
Enalapril MaleateTablet5 mg/1OralRebel Distributors Corp2009-12-11Not applicableUs
Enalapril MaleateTablet10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-12-11Not applicableUs
Enalapril MaleateTablet2.5 mg/1OralUnit Dose Services2009-12-11Not applicableUs
Enalapril MaleateTablet5 mg/1OralREMEDYREPACK INC.2012-10-03Not applicableUs
Enalapril MaleateTablet20 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Enalapril MaleateTablet2.5 mg/1OralWockhardt Limited2009-12-11Not applicableUs
Enalapril MaleateTablet20 mg/1OralMajor Pharmaceuticals2004-02-03Not applicableUs
Enalapril MaleateTablet20 mg/1OralWockhardt USA LLC.2009-12-11Not applicableUs
Enalapril MaleateTablet20 mg/1OralA S Medication Solutions2000-08-23Not applicableUs
Enalapril MaleateTablet20 mg/1OralLegacy Pharmaceutical Packaging, Llc2009-12-11Not applicableUs
Enalapril MaleateTablet20 mg/1OralUnit Dose Services2009-12-112016-11-22Us
Enalapril MaleateTablet10 mg/1OralBlenheim Pharmacal, Inc.2014-02-20Not applicableUs
Enalapril MaleateTablet20 mg/1OralTeva Pharmaceuticals USA Inc2000-08-23Not applicableUs
Enalapril MaleateTablet5 mg/1OralLake Erie Medical DBA Quality Care Products LLC2009-12-11Not applicableUs
Enalapril MaleateTablet20 mg/1OralNorthwind Pharmaceuticals, LLC2014-12-09Not applicableUs
Enalapril MaleateTablet20 mg/1OralREMEDYREPACK INC.2013-03-152016-11-01Us
Enalapril MaleateTablet20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2000-08-22Not applicableUs
Enalapril MaleateTablet2.5 mg/1OralMed Health Pharma, LLC2011-01-01Not applicableUs
Enalapril MaleateTablet10 mg/1OralREMEDYREPACK INC.2014-06-03Not applicableUs
Enalapril MaleateTablet5 mg/1OralCardinal Health2010-10-13Not applicableUs
Enalapril MaleateTablet10 mg/1Oralbryant ranch prepack2009-12-11Not applicableUs
Enalapril MaleateTablet20 mg/1OralGolden State Medical Supply, Inc.2013-11-04Not applicableUs
Enalapril MaleateTablet20 mg/1OralAmerican Health Packaging2009-05-26Not applicableUs
Enalapril MaleateTablet20 mg/1OralProficient Rx LP2009-12-11Not applicableUs
Enalapril MaleateTablet, soluble20 mg/1OralApace Packaging2009-08-22Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AcetecAlphapharm
AcetensilGrünenthal
AlaprenRanbaxy
AmotacMass Pharma
AmpraceMerck Sharp & Dohme
DilvasCipla
DiotensilMintlab
DrepatilFada
EnaceAbbott
EnaHexalSandoz
EnalEast West
EnalapotenDel Bel
EnprilWockhardt
FeliberalSilanes
GadoprilGador (Argentina)
GliotenBago
KinfilNova Argentia (Argentina)
Vasotec IVSandoz (Canada)
Brand mixtures
NameLabellerIngredients
Apo-enalapril Maleate/hctzApotex Inc
Enalapril Maleate and HydrochlorothiazideTeva Pharmaceuticals USA Inc
Enalapril/hctzFrosst A Division Of Merck Canada Inc
Teva-enalapril/hctzTeva Canada Limited
VasereticValeant Pharmaceuticals North America LLC
Salts
Name/CASStructureProperties
Enalapril maleate
ThumbNot applicableDBSALT001036
Enalapril sodium
ThumbNot applicableDBSALT001143
Categories
UNII69PN84IO1A
CAS number75847-73-3
WeightAverage: 376.4467
Monoisotopic: 376.199822016
Chemical FormulaC20H28N2O5
InChI KeyGBXSMTUPTTWBMN-XIRDDKMYSA-N
InChI
InChI=1S/C20H28N2O5/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25)/t14-,16-,17-/m0/s1
IUPAC Name
(2S)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]pyrrolidine-2-carboxylic acid
SMILES
CCOC(=O)[[email protected]](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[[email protected]]1C(O)=O
Pharmacology
IndicationFor the treatment of essential or renovascular hypertension and symptomatic congestive heart failure. It may be used alone or in combination with thiazide diuretics.
Structured Indications
PharmacodynamicsEnalapril is a prodrug that is rapidly metabolized by liver esterases to enalaprilat following oral administration. Enalapril itself has little pharmacologic activity. Enalaprilat lowers blood pressure by antagonizing the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may sustain the effects of enalaprilat by causing increased vasodilation and decreased blood pressure.
Mechanism of actionThere are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Enalaprilat, the principle active metabolite of enalapril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Enalapril also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors. Enalaprilat's affinity for ACE is approximately 200,000 times greater than that of ATI and 300-1000 times greater than that enalapril.
TargetKindPharmacological actionActionsOrganismUniProt ID
Angiotensin-converting enzymeProteinyes
inhibitor
HumanP12821 details
Related Articles
Absorption55-75%, absorption is unaffected by food; enalaprilat (clinically administered IV) is poorly absorbed, 3-12%, due to its high polarity.
Volume of distributionNot Available
Protein binding50-60% of enalaprilat is bound to plasma proteins
Metabolism

~ 60% of absorbed dose is extensively hydrolyzed to enalaprilat, primarily by liver esterases

SubstrateEnzymesProduct
Enalapril
Not Available
EnalaprilatDetails
Route of eliminationExcretion of enalapril is primarily renal.
Half life< 2 hours for unchanged enalapril in health individuals, may be increased in those with congestive heart failure (3.4 and 5.8 hours for single 5- and 10-mg doses, respectively). The average terminal half life of enalaprilat is 35-38 hours. The effective half life following multiple doses is 11-14 hours.
ClearanceNot Available
ToxicityOverdosage may result in marked hypotension and stupor. Most common adverse effects include hypotension, headache, dizziness and fatigue.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Enalapril Action PathwayDrug actionSMP00148
Enalapril Metabolism PathwayDrug metabolismSMP00593
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Enalapril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Enalapril.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Enalapril is combined with Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Enalapril is combined with Aceclofenac.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Enalapril.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Enalapril is combined with Acetazolamide.Approved, Vet Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Enalapril is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Enalapril.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Enalapril is combined with Adapalene.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Enalapril.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Enalapril.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Enalapril.Experimental
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Enalapril.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Enalapril.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Enalapril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Enalapril.Approved
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Enalapril.Approved
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Enalapril.Approved, Illicit, Investigational
AlprenololEnalapril may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Enalapril.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Enalapril.Experimental
AmifostineEnalapril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Enalapril is combined with Amiloride.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Enalapril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Enalapril.Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Enalapril.Approved
AmiodaroneThe metabolism of Enalapril can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Enalapril.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Enalapril.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Enalapril.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Enalapril is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Enalapril is combined with Amyl Nitrite.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Enalapril is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Enalapril is combined with Antipyrine.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Enalapril.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Enalapril is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Enalapril is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Enalapril is combined with Apremilast.Approved, Investigational
AprepitantThe serum concentration of Enalapril can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Enalapril.Approved, Withdrawn
ArdeparinArdeparin may increase the hyperkalemic activities of Enalapril.Approved, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Enalapril.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Enalapril is combined with Arotinolol.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Enalapril.Approved, Investigational
AtazanavirThe metabolism of Enalapril can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Enalapril.Approved
AtomoxetineThe metabolism of Enalapril can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Enalapril.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Enalapril.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Enalapril is combined with Azapropazone.Withdrawn
AzathioprineEnalapril may increase the myelosuppressive activities of Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Enalapril is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Enalapril.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Enalapril is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Enalapril.Experimental
BarbitalBarbital may increase the hypotensive activities of Enalapril.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Enalapril is combined with Barnidipine.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Enalapril.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Enalapril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Enalapril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Enalapril.Withdrawn
BenoxaprofenThe risk or severity of adverse effects can be increased when Enalapril is combined with Benoxaprofen.Withdrawn
BepridilEnalapril may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Enalapril.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Enalapril.Approved
BethanidineBethanidine may increase the hypotensive activities of Enalapril.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Enalapril is combined with Betulinic Acid.Investigational
BexaroteneThe serum concentration of Enalapril can be decreased when it is combined with Bexarotene.Approved, Investigational
BimatoprostEnalapril may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Enalapril is combined with Bisoprolol.Approved
BoceprevirThe serum concentration of Enalapril can be decreased when it is combined with Boceprevir.Approved
BortezomibThe metabolism of Enalapril can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Enalapril can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Enalapril.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Enalapril.Approved
BretyliumThe risk or severity of adverse effects can be increased when Enalapril is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Enalapril.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Enalapril.Approved
BromfenacThe risk or severity of adverse effects can be increased when Enalapril is combined with Bromfenac.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Enalapril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Enalapril is combined with Bucillamine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Enalapril is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Enalapril is combined with Bupivacaine.Approved, Investigational
BupranololEnalapril may increase the hypotensive activities of Bupranolol.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Enalapril.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Enalapril.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Enalapril.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Enalapril.Experimental
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Enalapril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Enalapril.Approved
CandoxatrilEnalapril may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Captopril.Approved
CarbamazepineThe metabolism of Enalapril can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Enalapril is combined with Carbetocin.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Enalapril.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Enalapril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Enalapril is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Enalapril.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Enalapril is combined with Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Enalapril is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Enalapril is combined with Celecoxib.Approved, Investigational
CeliprololEnalapril may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Enalapril can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Enalapril.Withdrawn
CertoparinCertoparin may increase the hyperkalemic activities of Enalapril.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Enalapril is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Enalapril is combined with Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Enalapril.Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Enalapril.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Enalapril.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Enalapril is combined with Cilnidipine.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Enalapril.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Enalapril.Approved, Investigational
CiprofloxacinEnalapril may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Enalapril.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Enalapril.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Enalapril.Approved
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Enalapril.Approved
ClemastineThe metabolism of Enalapril can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Enalapril is combined with Clevidipine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Enalapril.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Enalapril is combined with Clofarabine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Enalapril.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Enalapril.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Enalapril.Approved
ClonixinThe risk or severity of adverse effects can be increased when Enalapril is combined with Clonixin.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Enalapril.Approved, Nutraceutical
ClotrimazoleThe metabolism of Enalapril can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Enalapril.Approved
CobicistatThe metabolism of Enalapril can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Enalapril.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Enalapril.Approved
ConivaptanThe serum concentration of Enalapril can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Enalapril.Approved
CrizotinibThe metabolism of Enalapril can be decreased when combined with Crizotinib.Approved
CryptenamineEnalapril may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Enalapril is combined with Curcumin.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Enalapril.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Enalapril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Enalapril.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Enalapril can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideEnalapril may increase the hypotensive activities of Cyclothiazide.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Enalapril is combined with D-Limonene.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Enalapril.Approved
DabrafenibThe serum concentration of Enalapril can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Enalapril.Approved
DalteparinDalteparin may increase the hyperkalemic activities of Enalapril.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Enalapril is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Enalapril.Investigational
DarunavirThe metabolism of Enalapril can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Enalapril can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Enalapril.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Enalapril.Approved
DeferasiroxThe serum concentration of Enalapril can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Enalapril.Approved
dersalazinedersalazine may decrease the antihypertensive activities of Enalapril.Investigational
DeserpidineEnalapril may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Enalapril is combined with Desflurane.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Enalapril.Approved
DexamethasoneThe serum concentration of Enalapril can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Enalapril is combined with Dexmedetomidine.Approved, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Enalapril.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Enalapril.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Enalapril is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Enalapril is combined with Diclofenamide.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Enalapril.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Enalapril.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Enalapril.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Enalapril.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Enalapril.Approved
DihydralazineEnalapril may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Enalapril.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Enalapril.Illicit
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Enalapril.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Enalapril is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Enalapril is combined with Dipyridamole.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Enalapril.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Enalapril.Approved, Investigational, Vet Approved
DorzolamideEnalapril may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Enalapril.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Enalapril is combined with Doxazosin.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Enalapril.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Enalapril.Approved, Investigational
DoxycyclineThe metabolism of Enalapril can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Enalapril can be decreased when combined with Dronedarone.Approved
DrospirenoneEnalapril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Enalapril is combined with Droxicam.Approved
DuloxetineEnalapril may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Enalapril is combined with Duvelisib.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Enalapril.Approved
E6201The risk or severity of adverse effects can be increased when Enalapril is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Enalapril is combined with Ebselen.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Enalapril.Approved
EfavirenzThe serum concentration of Enalapril can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineEnalapril may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Enalapril.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Enalapril is combined with Empagliflozin.Approved
EnalaprilatEnalapril may increase the hypotensive activities of Enalaprilat.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Enalapril.Approved, Investigational
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Enalapril.Approved
EnzalutamideThe serum concentration of Enalapril can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Enalapril.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Enalapril is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Enalapril.Approved
EpoprostenolEnalapril may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Enalapril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Enalapril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Enalapril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Enalapril.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Enalapril.Approved, Investigational
ErythromycinThe metabolism of Enalapril can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Enalapril can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Enalapril.Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Enalapril.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Enalapril.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Enalapril.Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Enalapril.Approved, Vet Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Enalapril.Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Enalapril.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Enalapril.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Enalapril is combined with Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Enalapril is combined with Etanercept.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Enalapril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Enalapril is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Enalapril is combined with Etofenamate.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Enalapril.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Enalapril is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Enalapril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Enalapril is combined with Evening primrose oil.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Enalapril.Approved
exisulindThe risk or severity of adverse effects can be increased when Enalapril is combined with exisulind.Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Enalapril.Approved
FelodipineThe risk or severity of adverse effects can be increased when Enalapril is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Enalapril is combined with Fenbufen.Approved
FenoldopamEnalapril may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Enalapril is combined with Fenoprofen.Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Enalapril.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Enalapril.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Enalapril.Approved
FimasartanThe risk or severity of adverse effects can be increased when Enalapril is combined with Fimasartan.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Enalapril is combined with Floctafenine.Approved, Withdrawn
FluconazoleThe metabolism of Enalapril can be decreased when combined with Fluconazole.Approved
FlunixinThe risk or severity of adverse effects can be increased when Enalapril is combined with Flunixin.Vet Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Enalapril is combined with Flurbiprofen.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Enalapril.Approved
FluvoxamineThe metabolism of Enalapril can be decreased when combined with Fluvoxamine.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Enalapril.Experimental
FosamprenavirThe metabolism of Enalapril can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Enalapril can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Enalapril.Approved
FosphenytoinThe metabolism of Enalapril can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Enalapril.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Enalapril is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Enalapril can be increased when it is combined with Fusidic Acid.Approved
GarlicThe serum concentration of Enalapril can be decreased when it is combined with Garlic.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Enalapril.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Enalapril.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Enalapril.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Enalapril.Withdrawn
GuanabenzEnalapril may increase the hypotensive activities of Guanabenz.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Enalapril.Approved
GuanethidineEnalapril may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Enalapril is combined with Guanfacine.Approved, Investigational
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Enalapril.Approved
HalothaneThe risk or severity of adverse effects can be increased when Enalapril is combined with Halothane.Approved, Vet Approved
HeparinHeparin may increase the hyperkalemic activities of Enalapril.Approved, Investigational
HexamethoniumEnalapril may increase the hypotensive activities of Hexamethonium.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Enalapril.Withdrawn
HexobarbitalHexobarbital may increase the hypotensive activities of Enalapril.Approved
HigenamineThe risk or severity of adverse effects can be increased when Enalapril is combined with Higenamine.Investigational
HMPL-004The risk or severity of adverse effects can be increased when Enalapril is combined with HMPL-004.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Enalapril.Approved
HydralazineThe risk or severity of adverse effects can be increased when Enalapril is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Enalapril is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Enalapril.Approved, Vet Approved
HydroflumethiazideEnalapril may increase the hypotensive activities of Hydroflumethiazide.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Enalapril.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Enalapril is combined with Ibuproxam.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Enalapril.Approved
IdelalisibThe serum concentration of Enalapril can be increased when it is combined with Idelalisib.Approved
IloprostIloprost may increase the hypotensive activities of Enalapril.Approved, Investigational
ImatinibThe metabolism of Enalapril can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Enalapril.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Enalapril.Approved
IndapamideThe risk or severity of adverse effects can be increased when Enalapril is combined with Indapamide.Approved
IndenololEnalapril may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Enalapril can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Enalapril.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Enalapril is combined with Indoprofen.Withdrawn
IndoraminEnalapril may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Enalapril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Enalapril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Enalapril.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Enalapril.Approved, Investigational
IronThe risk or severity of adverse effects can be increased when Enalapril is combined with Iron.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Enalapril is combined with Iron Dextran.Approved, Vet Approved
IsavuconazoniumThe metabolism of Enalapril can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Enalapril.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Enalapril is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Enalapril is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Enalapril is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Enalapril is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Enalapril is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Enalapril.Approved
ItraconazoleThe metabolism of Enalapril can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Enalapril can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Enalapril.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Enalapril is combined with Kebuzone.Experimental
KetanserinEnalapril may increase the hypotensive activities of Ketanserin.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Enalapril.Approved
KetoconazoleThe metabolism of Enalapril can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Enalapril is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Enalapril is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Enalapril is combined with Labetalol.Approved
LacidipineEnalapril may increase the hypotensive activities of Lacidipine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Enalapril.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Enalapril.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Enalapril.Approved, Investigational
Lanthanum carbonateThe serum concentration of Enalapril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostEnalapril may increase the hypotensive activities of Latanoprost.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Enalapril.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Enalapril is combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Enalapril.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Enalapril.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Enalapril.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Enalapril.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Enalapril is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Enalapril is combined with Levobupivacaine.Approved
LevodopaEnalapril may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Enalapril.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Enalapril.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Enalapril is combined with Levosimendan.Approved, Investigational
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Enalapril.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Enalapril is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Enalapril.Approved
LofexidineEnalapril may increase the hypotensive activities of Lofexidine.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Enalapril.Approved
LopinavirThe metabolism of Enalapril can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Enalapril is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Enalapril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Enalapril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Enalapril is combined with Loxoprofen.Approved
LuliconazoleThe serum concentration of Enalapril can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Enalapril can be increased when combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Enalapril is combined with Lumiracoxib.Approved, Investigational
MacitentanEnalapril may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Enalapril is combined with Magnesium salicylate.Approved
ManidipineEnalapril may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Enalapril is combined with Mannitol.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Enalapril is combined with Masoprocol.Approved
MebanazineMebanazine may increase the hypotensive activities of Enalapril.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Enalapril is combined with Mecamylamine.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Enalapril is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Enalapril is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Enalapril is combined with Meloxicam.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Enalapril.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Enalapril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Enalapril is combined with Metamizole.Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Enalapril.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Enalapril is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Enalapril.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Enalapril.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Enalapril.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Enalapril is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Enalapril.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Enalapril.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Enalapril.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Enalapril.Approved, Vet Approved
MetipranololThe risk or severity of adverse effects can be increased when Enalapril is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Enalapril.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Enalapril.Approved, Investigational
MetyrosineEnalapril may increase the hypotensive activities of Metyrosine.Approved
MibefradilEnalapril may increase the hypotensive activities of Mibefradil.Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Enalapril.Approved, Illicit
MifepristoneThe serum concentration of Enalapril can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Enalapril.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Enalapril.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Enalapril.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Enalapril.Approved
MitotaneThe serum concentration of Enalapril can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Enalapril.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Enalapril is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Enalapril.Approved
ModafinilThe serum concentration of Enalapril can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Enalapril.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Enalapril.Approved, Investigational
MoxonidineEnalapril may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Enalapril.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Enalapril is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Enalapril is combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Enalapril is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Enalapril is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Enalapril.Approved
NafamostatThe risk or severity of adverse effects can be increased when Enalapril is combined with Nafamostat.Investigational
NafcillinThe serum concentration of Enalapril can be decreased when it is combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Enalapril is combined with Naftifine.Approved
NaftopidilEnalapril may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Enalapril.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Enalapril.Approved, Vet Approved
NaproxenThe risk or severity of adverse effects can be increased when Enalapril is combined with Naproxen.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when Enalapril is combined with NCX 4016.Investigational
NebivololThe risk or severity of adverse effects can be increased when Enalapril is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Enalapril.Approved, Withdrawn
NelfinavirThe metabolism of Enalapril can be decreased when combined with Nelfinavir.Approved
NepafenacThe risk or severity of adverse effects can be increased when Enalapril is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Enalapril is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Enalapril can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Enalapril can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Enalapril.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Enalapril is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Enalapril.Approved
NifedipineThe risk or severity of adverse effects can be increased when Enalapril is combined with Nifedipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Enalapril is combined with Niflumic Acid.Approved
NiguldipineEnalapril may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe metabolism of Enalapril can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineEnalapril may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Enalapril is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Enalapril.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Enalapril.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Enalapril.Approved
NitrendipineEnalapril may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Enalapril is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Enalapril.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Enalapril is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Enalapril.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Enalapril.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Enalapril.Approved
ObinutuzumabEnalapril may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Enalapril.Withdrawn
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Enalapril.Approved, Investigational
OlaparibThe metabolism of Enalapril can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Enalapril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Enalapril is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Enalapril is combined with Olsalazine.Approved
OmapatrilatEnalapril may increase the hypotensive activities of Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Enalapril.Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Enalapril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Enalapril is combined with Orgotein.Vet Approved
OsimertinibThe serum concentration of Enalapril can be increased when it is combined with Osimertinib.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Enalapril is combined with Oxaprozin.Approved
OxprenololEnalapril may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Enalapril is combined with Oxyphenbutazone.Withdrawn
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Enalapril.Approved, Vet Approved
PalbociclibThe serum concentration of Enalapril can be increased when it is combined with Palbociclib.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Enalapril.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Enalapril is combined with Papaverine.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Enalapril is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Enalapril.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Enalapril.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Enalapril.Approved
PenbutololThe risk or severity of adverse effects can be increased when Enalapril is combined with Penbutolol.Approved, Investigational
PentobarbitalThe metabolism of Enalapril can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumEnalapril may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Enalapril.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Enalapril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Enalapril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Enalapril.Withdrawn
PhenobarbitalThe metabolism of Enalapril can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineEnalapril may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Enalapril.Withdrawn
PhentolamineEnalapril may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Enalapril is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Enalapril can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Enalapril is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Enalapril.Approved
PinacidilEnalapril may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Enalapril is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Enalapril is combined with Pipamperone.Approved
PiretanidePiretanide may increase the hypotensive activities of Enalapril.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Enalapril is combined with Pirfenidone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Enalapril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Enalapril is combined with Piroxicam.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Enalapril.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Enalapril.Withdrawn
PolythiazideEnalapril may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Enalapril.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Enalapril.Approved
PosaconazoleThe metabolism of Enalapril can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Enalapril is combined with Pramipexole.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Enalapril.Approved
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Enalapril.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Enalapril.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Enalapril.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Enalapril is combined with Pregabalin.Approved, Illicit, Investigational
PrimidoneThe metabolism of Enalapril can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Enalapril.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Enalapril is combined with Propacetamol.Approved
PropofolThe risk or severity of adverse effects can be increased when Enalapril is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Enalapril.Approved, Investigational
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Enalapril.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Enalapril.Approved
PTC299The risk or severity of adverse effects can be increased when Enalapril is combined with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Enalapril is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Quinapril.Approved, Investigational
QuinethazoneQuinethazone may increase the hypotensive activities of Enalapril.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Enalapril.Approved
QuinineQuinine may increase the hypotensive activities of Enalapril.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Enalapril.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Enalapril.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Enalapril.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Enalapril.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Enalapril is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Enalapril.Approved
RescinnamineEnalapril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Enalapril.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Enalapril is combined with Resveratrol.Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Enalapril.Approved
RifabutinThe metabolism of Enalapril can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Enalapril can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Enalapril can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Enalapril.Approved, Investigational
RilmenidineEnalapril may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Enalapril.Approved
RisperidoneEnalapril may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Enalapril can be decreased when combined with Ritonavir.Approved, Investigational
RituximabEnalapril may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Enalapril.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Enalapril is combined with Rofecoxib.Investigational, Withdrawn
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Enalapril.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Enalapril is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Enalapril is combined with Ropivacaine.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Enalapril.Approved
RotigotineThe risk or severity of adverse effects can be increased when Enalapril is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Enalapril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Enalapril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Enalapril is combined with Salicylamide.Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Enalapril.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Enalapril is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Enalapril.Experimental
SaquinavirThe metabolism of Enalapril can be decreased when combined with Saquinavir.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Enalapril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Enalapril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Enalapril.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Enalapril.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Enalapril.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Enalapril is combined with Seratrodast.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Enalapril is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Enalapril.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Enalapril.Approved
SiltuximabThe serum concentration of Enalapril can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Enalapril.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Enalapril.Approved
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Enalapril.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Enalapril.Approved, Investigational
SitaxentanEnalapril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Enalapril is combined with Sodium aurothiomalate.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Enalapril is combined with Sodium Nitrite.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Enalapril.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Enalapril.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Enalapril.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Enalapril.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Enalapril.Experimental
SpiraprilEnalapril may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Enalapril.Approved
SRT501The risk or severity of adverse effects can be increased when Enalapril is combined with SRT501.Investigational
St. John's WortThe metabolism of Enalapril can be increased when combined with St. John&#39;s Wort.Nutraceutical
StiripentolThe serum concentration of Enalapril can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Enalapril is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Enalapril is combined with Sufentanil.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Enalapril is combined with Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Enalapril can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Enalapril is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Enalapril is combined with Suprofen.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Enalapril.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Enalapril.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Enalapril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Enalapril.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Enalapril.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Enalapril is combined with Tamsulosin.Approved, Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Enalapril.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Enalapril.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Enalapril.Approved
TelaprevirThe metabolism of Enalapril can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Enalapril can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Enalapril.Approved, Investigational
TemocaprilEnalapril may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Enalapril is combined with Temsirolimus.Approved
TenoxicamThe risk or severity of adverse effects can be increased when Enalapril is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Enalapril is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Enalapril is combined with Terazosin.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Enalapril is combined with Teriflunomide.Approved
TerlipressinEnalapril may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Enalapril is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Enalapril.Approved
ThiamylalThiamylal may increase the hypotensive activities of Enalapril.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Enalapril.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Enalapril is combined with Thioridazine.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Enalapril.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Enalapril is combined with Tiaprofenic acid.Approved
TiboloneEnalapril may increase the hypotensive activities of Tibolone.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Enalapril.Approved
TiclopidineThe metabolism of Enalapril can be decreased when combined with Ticlopidine.Approved
TicrynafenEnalapril may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Enalapril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Enalapril is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Enalapril.Approved
TipranavirThe serum concentration of Enalapril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the hypotensive activities of Enalapril.Approved
TocilizumabThe serum concentration of Enalapril can be decreased when it is combined with Tocilizumab.Approved
TolazolineEnalapril may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Enalapril is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Enalapril is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Enalapril is combined with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Enalapril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Enalapril.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Enalapril.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Enalapril.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Enalapril.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Enalapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Enalapril is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Enalapril.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Enalapril.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Enalapril.Approved
TravoprostTravoprost may increase the hypotensive activities of Enalapril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Enalapril.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Enalapril is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Enalapril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Enalapril.Approved
TrichlormethiazideEnalapril may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinEnalapril may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanEnalapril may increase the hypotensive activities of Trimethaphan.Approved
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Enalapril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Enalapril.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Enalapril is combined with Trisalicylate-choline.Approved
UdenafilUdenafil may increase the antihypertensive activities of Enalapril.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Enalapril.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Enalapril.Approved
UnoprostoneEnalapril may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Enalapril is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Enalapril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Enalapril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Enalapril.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Enalapril.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Enalapril.Approved
VenlafaxineThe metabolism of Enalapril can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Enalapril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Enalapril.Approved, Investigational
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Enalapril.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Enalapril.Approved, Investigational
VinpocetineEnalapril may increase the hypotensive activities of Vinpocetine.Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Enalapril.Approved
VoriconazoleThe metabolism of Enalapril can be decreased when combined with Voriconazole.Approved, Investigational
XylometazolineEnalapril may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Enalapril.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Enalapril is combined with Zaltoprofen.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Enalapril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Enalapril is combined with Zileuton.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Enalapril can be decreased when combined with Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Enalapril is combined with Zomepirac.Withdrawn
Food Interactions
  • Enalapril decreases the excretion of potassium. Salt substitutes containing potassium increase the risk of hyperkalemia.
  • Herbs that may attenuate the antihypertensive effect of enalapril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of enalapril.
  • Take without regard to meals.
References
Synthesis Reference

K. S. Keshava Murthy, Andrew Burchat, Gamini Weeratunga, “Sodium enalapril complex and the use thereof to make sodium enalapril.” U.S. Patent US5637730, issued February, 1983.

US5637730
General References
  1. Florey, Klaus;Al-Badr, Abdullah A.;Brenner, Gerald S. (1987). Analytical Profiles of Drug Substances (16th ed.). Elsevier Science & Technology Books. [ISBN:978-0-12-260816-2 ]
External Links
ATC CodesC09BB06C09BB02C09AA02C09BA02
AHFS Codes
  • 24:32.04
PDB Entries
FDA labelDownload (939 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7428
Blood Brain Barrier-0.9659
Caco-2 permeable-0.8956
P-glycoprotein substrateSubstrate0.7691
P-glycoprotein inhibitor INon-inhibitor0.6681
P-glycoprotein inhibitor IINon-inhibitor0.5136
Renal organic cation transporterNon-inhibitor0.8442
CYP450 2C9 substrateNon-substrate0.8632
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5696
CYP450 1A2 substrateNon-inhibitor0.9125
CYP450 2C9 inhibitorNon-inhibitor0.9154
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6825
Ames testNon AMES toxic0.9383
CarcinogenicityNon-carcinogens0.9216
BiodegradationNot ready biodegradable0.8686
Rat acute toxicity1.8269 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9719
hERG inhibition (predictor II)Non-inhibitor0.7456
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Apotex inc
  • Apothecon inc div bristol myers squibb
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Krka dd novo mesto
  • Lek pharmaceuticals d d
  • Mylan pharmaceuticals inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Taro pharmaceutical industries ltd
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Wockhardt americas inc
  • Biovail laboratories international srl
  • Bedford laboratories div ben venue laboratories inc
  • Hikma farmaceutica (portugal) sa
  • Hospira inc
  • Teva parenteral medicines inc
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg
TabletOral2.5 mg
TabletOral20 mg
TabletOral5 mg
TabletOral10.0 mg
TabletOral20.0 mg
TabletOral5.0 mg
TabletOral10 mg/1
TabletOral2.5 mg/1
TabletOral20 mg/1
TabletOral5 mg/1
Tablet, solubleOral10 mg/1
Tablet, solubleOral2.5 mg/1
Tablet, solubleOral20 mg/1
Tablet, solubleOral5 mg/1
TabletOral
Kit
SolutionOral1 mg/mL
TabletOral2.0 mg
TabletOral4.0 mg
TabletOral8.0 mg
TabletOral16 mg
TabletOral32 mg
TabletOral4 mg
TabletOral8 mg
TabletOral2 mg
Prices
Unit descriptionCostUnit
Enalapril maleate powder9.18USD g
Enalaprilat 1.25 mg/ml vial3.6USD ml
Vasotec 20 mg tablet3.36USD tablet
Vaseretic 10-25 mg tablet3.15USD tablet
Vasotec 10 mg tablet2.63USD tablet
Vasotec 5 mg tablet2.08USD tablet
Vasotec 2.5 mg tablet1.65USD tablet
Enalapril maleate 20 mg tablet1.56USD tablet
Vaseretic 5-12.5 mg tablet1.49USD tablet
Vasotec 20 mg Tablet1.34USD tablet
Vasotec 10 mg Tablet1.11USD tablet
Enalapril maleate 10 mg tablet1.09USD tablet
Enalapril maleate 5 mg tablet1.03USD tablet
Vasotec 5 mg Tablet0.92USD tablet
Enalapril maleate 2.5 mg tablet0.82USD tablet
Vasotec 2.5 mg Tablet0.78USD tablet
Apo-Enalapril 20 mg Tablet0.75USD tablet
Co Enalapril 20 mg Tablet0.75USD tablet
Mylan-Enalapril 20 mg Tablet0.75USD tablet
Novo-Enalapril 20 mg Tablet0.75USD tablet
Pms-Enalapril 20 mg Tablet0.75USD tablet
Ratio-Enalapril 20 mg Tablet0.75USD tablet
Sandoz Enalapril 20 mg Tablet0.75USD tablet
Taro-Enalapril 20 mg Tablet0.75USD tablet
Apo-Enalapril 10 mg Tablet0.62USD tablet
Co Enalapril 10 mg Tablet0.62USD tablet
Mylan-Enalapril 10 mg Tablet0.62USD tablet
Novo-Enalapril 10 mg Tablet0.62USD tablet
Pms-Enalapril 10 mg Tablet0.62USD tablet
Ratio-Enalapril 10 mg Tablet0.62USD tablet
Sandoz Enalapril 10 mg Tablet0.62USD tablet
Taro-Enalapril 10 mg Tablet0.62USD tablet
Apo-Enalapril 5 mg Tablet0.52USD tablet
Co Enalapril 5 mg Tablet0.52USD tablet
Mylan-Enalapril 5 mg Tablet0.52USD tablet
Novo-Enalapril 5 mg Tablet0.52USD tablet
Pms-Enalapril 5 mg Tablet0.52USD tablet
Ratio-Enalapril 5 mg Tablet0.52USD tablet
Sandoz Enalapril 5 mg Tablet0.52USD tablet
Taro-Enalapril 5 mg Tablet0.52USD tablet
Apo-Enalapril 2.5 mg Tablet0.44USD tablet
Co Enalapril 2.5 mg Tablet0.44USD tablet
Mylan-Enalapril 2.5 mg Tablet0.44USD tablet
Novo-Enalapril 2.5 mg Tablet0.44USD tablet
Pms-Enalapril 2.5 mg Tablet0.44USD tablet
Ratio-Enalapril 2.5 mg Tablet0.44USD tablet
Sandoz Enalapril 2.5 mg Tablet0.44USD tablet
Taro-Enalapril 2.5 mg Tablet0.44USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8568747 No2012-11-062032-11-06Us
US8778366 No2012-11-062032-11-06Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point143-144.5 °CNot Available
water solubility1.64E+004 mg/L (at 25 °C)MCFARLAND,JW ET AL. (2001)
logP0.07HANSCH,C ET AL. (1995)
Caco2 permeability-5.64ADME Research, USCD
pKa2.97 (the carboxyl group) and 5.35 (the amine group) at 25°CNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.213 mg/mLALOGPS
logP0.19ALOGPS
logP0.59ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)3.67ChemAxon
pKa (Strongest Basic)5.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area95.94 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity99.57 m3·mol-1ChemAxon
Polarizability40.41 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentPeptides
Alternative Parents
Substituents
  • Alpha peptide
  • N-acyl-alpha amino acid or derivatives
  • N-acyl-alpha-amino acid
  • Alpha-amino acid ester
  • Alpha-amino acid amide
  • Phenylpropylamine
  • Alpha-amino acid or derivatives
  • N-substituted-alpha-amino acid
  • Pyrrolidine carboxylic acid or derivatives
  • Pyrrolidine carboxylic acid
  • N-acylpyrrolidine
  • Aralkylamine
  • Fatty acid ester
  • Fatty acyl
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • Tertiary amine
  • Carboxylic acid ester
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Secondary aliphatic amine
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:
ACE
Uniprot ID:
P12821
Molecular Weight:
149713.675 Da
References
  1. Andujar-Sanchez M, Jara-Perez V, Camara-Artigas A: Thermodynamic determination of the binding constants of angiotensin-converting enzyme inhibitors by a displacement method. FEBS Lett. 2007 Jul 24;581(18):3449-54. Epub 2007 Jun 27. [PubMed:17618628 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Liu YH, Liu LY, Wu JX, Chen SX, Sun YX: Comparison of captopril and enalapril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE inhibitors in high dieted methionine mice. J Cardiovasc Pharmacol. 2006 Jan;47(1):82-8. [PubMed:16424790 ]
  4. Natesh R, Schwager SL, Evans HR, Sturrock ED, Acharya KR: Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme. Biochemistry. 2004 Jul 13;43(27):8718-24. [PubMed:15236580 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Han H, de Vrueh RL, Rhie JK, Covitz KM, Smith PL, Lee CP, Oh DM, Sadee W, Amidon GL: 5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res. 1998 Aug;15(8):1154-9. [PubMed:9706043 ]
  2. Han HK, Rhie JK, Oh DM, Saito G, Hsu CP, Stewart BH, Amidon GL: CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs. J Pharm Sci. 1999 Mar;88(3):347-50. [PubMed:10052994 ]
  3. Temple CS, Boyd CA: Proton-coupled oligopeptide transport by rat renal cortical brush border membrane vesicles: a functional analysis using ACE inhibitors to determine the isoform of the transporter. Biochim Biophys Acta. 1998 Aug 14;1373(1):277-81. [PubMed:9733984 ]
  4. Tsuji A: Transporter-mediated Drug Interactions. Drug Metab Pharmacokinet. 2002;17(4):253-74. [PubMed:15618677 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Kuze K, Graves P, Leahy A, Wilson P, Stuhlmann H, You G: Heterologous expression and functional characterization of a mouse renal organic anion transporter in mammalian cells. J Biol Chem. 1999 Jan 15;274(3):1519-24. [PubMed:9880528 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Kobayashi Y, Ohshiro N, Tsuchiya A, Kohyama N, Ohbayashi M, Yamamoto T: Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. Drug Metab Dispos. 2004 May;32(5):479-83. [PubMed:15100168 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Kobayashi Y, Ohshiro N, Shibusawa A, Sasaki T, Tokuyama S, Sekine T, Endou H, Yamamoto T: Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice. Mol Pharmacol. 2002 Jul;62(1):7-14. [PubMed:12065749 ]
  2. Sekine T, Cha SH, Tsuda M, Apiwattanakul N, Nakajima N, Kanai Y, Endou H: Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82. [PubMed:9650585 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Abu-Zahra TN, Wolkoff AW, Kim RB, Pang KS: Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6. [PubMed:10859154 ]
  2. Pang KS, Wang PJ, Chung AY, Wolkoff AW: The modified dipeptide, enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein. Hepatology. 1998 Nov;28(5):1341-6. [PubMed:9794920 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 05, 2016 02:44